3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s78. https://doi.org/10.25251/skin.6.supp.78